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Because of genetic heterogeneity, the identification of breast cancer–susceptibility genes has proven to be exceedingly
difficult. Here, we define a new subset of families with breast cancer characterized by the presence of colorectal
cancer cases. The 1100delC variant of the cell cycle checkpoint kinase CHEK2 gene was present in 18% of 55
families with hereditary breast and colorectal cancer (HBCC) as compared with 4% of 380 families with non-
HBCC ( ), thus providing genetic evidence for the HBCC phenotype. The CHEK2 1100delC mutation was,P ! .001
however, not the major predisposing factor for the HBCC phenotype but appeared to act in synergy with another,
as-yet-unknown susceptibility gene(s). The unequivocal definition of the HBCC phenotype opens new avenues to
search for this putative HBCC-susceptibility gene.
Cell cycle checkpoint kinase 2 (CHEK2, also known as
“CHK2” [MIM 604373] and as “Cds1” in Schizosac-
charomyces pombe and “RAD53” in Saccharomyces
cerevisiae) is a key mediator in DNA damage–response
pathways (Zhou and Elledge 2000; Bartek et al. 2001;
Myung and Kolodner 2002; Rouse and Jackson 2002).
In the course of our search for new breast cancer genes,
we recently identified the kinase-deficient 1100delC vari-
ant of CHEK2 as a low-penetrance breast cancer–sus-
ceptibility allele (Meijers-Heijboer et al. 2002). The
prevalence of the CHEK2 1100delC mutation among
families with non-BRCA1/BRCA2 breast cancer was
4.2% as compared with 1.1% among healthy individu-
als, implying an estimated twofold increased risk to de-
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velop breast cancer for women carrying the mutant al-
lele. Similar results were then reported for Finnish families
with breast cancer, thus independently confirming our
observations (Vahteristo et al. 2002). We had noted that
several of the families with CHEK2 1100delC breast
cancer also included colorectal cancer cases, but its sig-
nificance had been unclear (H.M.-H. and M.S., unpub-
lished observations). Family EUR60, for example, en-
compassed six colorectal cancer cases, four of which had
been diagnosed before age 50 years, and none could be
explained by mutations of the APC (MIM 175100),
MLH1 (MIM 120436), MSH2 (MIM 120435), or
MSH6 (MIM 600678) genes (fig. 1). A subtype of fa-
milial breast cancer that includes colorectal cancer had
already been recognized by one of us in the early 1970s
(Lynch et al. 1972), but evidence for such a phenotype
has never been provided. Here, we have evaluated the
involvement of the CHEK2 1100delC mutation in co-
lorectal-cancer susceptibility.
Families with colorectal cancer were collected through
the International Concerted Action Polyp Prevention
(CAPP) and the Dutch Foundation for Detection of He-
reditary Tumors (STOET). Families with colorectal can-
Figure 1 Abridged pedigrees of families with HBCC breast cancer who carry the CHEK2 1100delC mutation. Tumor type and age at
diagnosis of the tumors are indicated below the individual identifiers. When known, the age of death (d:) is indicated below the tumor type
for those cases where the age at diagnosis was unknown. Data from unaffected individuals who are not obligate CHEK2 1100delC mutation
carriers are omitted to preserve confidentiality. For simplicity, unaffected family members of the youngest generations are also omitted. Ab-
breviations for the various tumor types: BCC p basal cell carcinoma; BLC p bladder cancer; BRAIN p brain cancer, BRC p breast cancer;
CIS p carcinoma in situ of the breast; CRCp colorectal cancer; CSUp cancer site unknown; GACp gastric cancer; LEUp leukemia; LUC
p lung cancer; nonH p non-Hodgkin lymphoma; PAC p pancreatic cancer; Polyps p adenomatous polyps in the colorectum; RCCp renal
cell carcinoma; and T-LY p T-cell lymphoma. Note that several individuals affected with early-onset cancer are noncarriers of the CHEK2
1100delC mutation, illustrating incomplete cosegregation (A and C). The high-penetrant cancer–predisposition pattern among all four families
contrasts the estimated twofold breast cancer risk associated with the CHEK2 1100delC mutation, supporting synergism of CHEK2 with the
putative HBCC-susceptibility gene(s).
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Table 1
Prevalence of the CHEK2 1100delC Mutation among Families with Colorectal Cancer
and Families with Breast Cancer
Cohorts and Subgroups CHEK2 1100delC/Total Tested
Controls (Meijers-Heijboer et al. 2002) 18/1620 (1.1%)
Families with colorectal cancer:
Families with FAP 0/95 (0.0%)
Families with HNPCC and HNPCC-like disease: 6/234 (2.6%)
MLH1-positive 1/61
MSH2-positive 1/58
MSH6-positive 1/8
Non-MLH1/MSH2/MSH6 3/107
Families with non-BRCA1/BRCA2 breast cancer: 25/435 (5.8%)
Families with HBCC: 10/55 (18.2%)
Cohort 1 4/30
Cohort 2 6/25
Families with non-HBCC: 15/380 (4.0%)
Cohort 1 8/158
Cohort 2 7/222
cer were classified by clinical and genetic criteria, re-
sulting in two main groups of (i) families with familial
adenomatous polyposis (FAP [MIM 175100]), charac-
terized by 1100 adenomatous polyps in the colorectum
( ) or 120 polyps in the case of attenuated FAPnp 91
( ), and (ii) families with hereditary nonpolyposisnp 4
colorectal cancer (HNPCC [MIM 114500]) or with a
phenotype reminiscent of HNPCC ( 4), definednp 23
by at least two patients with colorectal cancer who were
first-degree relatives, of whom at least one had been
diagnosed before age 50 years. Pathogenic mutations of
the APC gene were identified in 61 of 95 families with
FAP and of the MLH1, MSH2, or MSH6 genes in 127
families with HNPCC (table 1). Extensive mutational
analyses had failed to identify mutations of these genes
in the index cases of the remaining 34 families with FAP
and 107 families with HNPCC and HNPCC-like disease.
Of the 107 mutation-negative families with HNPCC and
HNPCC-like disease, 70 met the Amsterdam criteria for
HNPCC. Mutational analyses included the complete
coding sequences of the APC, MLH1, MSH2, and MSH6
genes, as well as all known Dutch founder mutations and
deletions, as described elsewhere (van der Luijt et al.
1997; Wijnen et al. 1997, 1998, 1999). All families with
breast cancer had been clinically ascertained through the
Rotterdam family cancer clinic. Families with breast can-
cer were defined by at least two patients with breast cancer
who were first- or second-degree relatives, of whom at
least one had been diagnosed before age 60 years. A first
cohort of families with non-BRCA1/BRCA2 breast can-
cer ( ) was described elsewhere, as part of a studynp 188
by the International CHEK2-Breast Cancer Consortium
(Meijers-Heijboer et al. 2002). Note that we used more
stringent inclusion criteria for the current study, resulting
in minor differences between the data sets. A second
cohort of families with non-BRCA1/BRCA2 breast can-
cer ( ) did not overlap with the first cohort, andnp 247
the CHEK2 1100delC mutation status was unknown
prior to this study. Both cohorts of families with breast
cancer were excluded for pathogenic mutations of the
BRCA1 (MIM 113705) or BRCA2 (MIM 600185) genes
by mutational analyses of the complete coding sequences
of both genes, as well as screening for all known Dutch
founder mutations and deletions, as described elsewhere
(Petrij-Bosch et al. 1997; Meijers-Heijboer et al. 2002).
Informed consents to search for the cancer-susceptibility
genes have been obtained for all families, and all studies
have been approved by local medical ethical committees.
We determined the prevalence of the CHEK2 1100delC
mutation in a cohort of 329 families with colorectal
cancer (table 1). DNA from a blood sample of the index
case of each family was screened for the CHEK2
1100delC mutation by an allele-specific oligohybridi-
zation assay (Meijers-Heijboer et al. 2002), and all posi-
tive samples were confirmed by direct sequencing of in-
dependently amplified templates (Sodha et al. 2002). The
CHEK2 1100delC mutation was not identified in any
of 95 families with FAP. Of the 234 families with
HNPCC or HNPCC-like disease, 6 (2.6%) carried the
CHEK2 1100delC mutation. Mutational analysis of the
three main mismatch-repair genes had previously de-
tected a germline mutation of MLH1, MSH2, or MSH6
in three of the six families with CHEK2 1100delC co-
lorectal cancer but had failed to identify pathogenic se-
quence variants in the other three families (table 1). Al-
though the prevalence of the CHEK2 1100delC mutation
among the families with HNPCC and HNPCC-like dis-
ease was somewhat higher than among control subjects,
this difference was not significant (2.6% vs. 1.1%; odds
ratio [OR] 2.34; 95% CI 0.95–5.79; ).Pp .07
The presence of colorectal cancer cases in some of the
families with CHEK2 1100delC breast cancer prompted
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Table 2
Particulars of the Families with Non-BRCA1/BRCA2 Breast Cancer
FINDING IN FAMILIES WITH BREAST CANCER
P
With CHEK2 1100delC
(%)
Without CHEK2 1100delC
(%)
HBCC Non-HBCC All HBCC Non-HBCC All
Average age at diagnosis of index cases 43.8 46.6 45.5 46.7 45.8 45.8 .87a
Families including patients with bilateral BRC 3 (30) 2 (13) 5 (20) 13 (29) 96 (26) 109 (27) .45a
Number of patients with BRC in the family:
One patient diagnosed at age !60 years 1 (10) 5 (33) 6 (24) 14 (31) 84 (23) 98 (24)
Two patients diagnosed at age !60 years 3 (30) 5 (33) 8 (32) 17 (38) 151 (41) 168 (41)
Three patients diagnosed at age !60 years 2 (20) 2 (13) 4 (16) 6 (13) 80 (22) 86 (21)
More than three patients diagnosed at age
!60 years
4 (40) 3 (20) 7 (28) 8 (18) 50 (14) 58 (14) .29a
Total number of families with breast cancer 10 (40) 15 25 45 (11) 365 410 !.001b
a P value for the difference between all families with CHEK2 1100delC-positive and CHEK2 1100delC-negative breast cancer.
b P value for the difference between families with CHEK2 1100delC-positive and CHEK2 1100delC-negative HBCC.
us to further analyze our original cohort of families with
breast cancer from the Rotterdam family cancer clinic
(Meijers-Heijboer et al. 2002). In this cohort, the preva-
lence of the CHEK2 1100delC mutation was 6.4%
among the families with non-BRCA1/BRCA2 breast can-
cer (12 of 188 families; table 1). We then set to classify
the families with breast cancer within this cohort by more
stringent clinical criteria that defined a putative hereditary
breast and colorectal cancer phenotype (HBCC). We de-
fine a “family with the HBCC phenotype” as a family
with breast cancer characterized by the presence of at
least two patients with breast cancer who were first- or
second-degree relatives and of whom at least one is di-
agnosed before age 60 years and
1. at least one patient with breast cancer and colo-
rectal cancer diagnosed at any age; or
2. at least one individual with colorectal cancer diag-
nosed before age 50 years who was a first- or second-
degree relative of a patient with breast cancer; or
3. at least two patients with colorectal cancer diag-
nosed at any age of whom at least one was a first-
or second-degree relative of a patient with breast
cancer.
(An anamnestic report of colorectal cancer was consid-
ered reliable only when the diagnosis had been made after
1960.) Of the 188 families with breast cancer, 30 met
our clinical criteria for HBCC (table 1). Four of these
30 (13.3%) families with HBCC carried the CHEK2
1100delC mutation, suggesting that the mutant allele in-
deed identified an HBCC phenotype. Such retrospectively
defined criteria are, however, inherently subjective. We
therefore applied the HBCC criteria prospectively to an-
other cohort of 247 families with non-BRCA1/BRCA2
breast cancer from the Rotterdam family cancer clinic.
This second cohort of families with breast cancer did
not overlap with the first cohort, and the CHEK2
1100delC mutation status of the families was unknown.
Of the 247 families with breast cancer from this second
cohort, 25 met our clinical criteria for HBCC (table 1).
Of these 25 families with HBCC, 6 (24.0%) carried the
CHEK2 1100delC mutation, as compared with 7 of 222
(3.2%) families with non-HBCC from this cohort, thereby
confirming the strong association of the HBCC pheno-
type with the CHEK2 1100delC mutation.
Identification of a similar phenotype with an increased
risk of breast cancer among families with colorectal can-
cer was not unequivocal. When “mirror” HBCC criteria
were applied to our cohort of families with colorectal
cancer, comparable with the HBCC criteria for families
with breast cancer (see list above), 44 of the 234 families
with HNPCC and HNPCC-like disease met these criteria.
Of these 44 families with HBCC-like colorectal cancer,
2 (4.5%) carried the CHEK2 1100delC mutation, as
compared with 4 of the 190 (2.1%) remaining families
with HNPCC and HNPCC-like disease. Although these
data may suggest an “HBCC-like” phenotype for fami-
lies with colorectal cancer similar to that of families with
HBCC breast cancer, the evidence is circumstantial and
awaits further evaluation. We anticipate that the CHEK2
1100delC mutation does confer a colorectal cancer risk
but that this risk is even lower than its rather modest
breast cancer risk of twofold. Substantially larger series
of families with HNPCC and HNPCC-like disease would
thus be required to reach sufficient statistical power to
identify such a low-penetrance colorectal-cancer risk.
Altogether, we identified the CHEK2 1100delC mu-
tation in 10 of 55 (18.2%) families with HBCC, com-
pared with 15 of 380 (4.0%) families with non-HBCC
breast cancer (OR 5.41; 95% CI 2.29–12.8; ).P ! .001
To evaluate the influence of other parameters thought
to associate with the CHEK2 1100delC mutation, we
performed univariate and multivariate analyses on all 435
families with non-BRCA1/BRCA2 breast cancer from the
two Rotterdam family cohorts (table 2). Consistent with
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our report elsewhere (Meijers-Heijboer et al. 2002), but
in contrast with the Finnish report (Vahteristo et al.
2002), the prevalence of the CHEK2 1100delC mutation
was increased among families with more than three
members with breast cancer diagnosed before age 60
years (11% vs. 5%; OR 2.36; 95% CI 0.94–5.90; Pp
). Consistent with both reports (Meijers-Heijboer et.07
al. 2002; Vahteristo et al. 2002), there was no difference
in the age at breast cancer diagnosis for the index cases
of the families with CHEK2 1100delC breast cancer, as
compared with the index cases of families without the
mutant allele (45.5 vs. 45.8 years). The prevalence of
the CHEK2 1100delC mutation was similar among fami-
lies with and without patients with bilateral breast can-
cer (4.4% versus 6.2%). Cases of male breast cancer
were not observed in any of the families with CHEK2
1100delC breast cancer (Meijers-Heijboer et al. 2002).
No significant differences between the families with
HBCC and non-HBCC breast cancer were observed for
any of the parameters, except for the prevalence of the
CHEK2 1100delC mutation (table 2). The association
of the CHEK2 1100delC mutation with the HBCC phe-
notype remained strong after correction for the number
of breast cancer cases diagnosed before age 60 years and
the presence of bilateral breast cancer cases in the family
(multivariate OR 5.19; 95% CI 2.17–12.4; ).P ! .001
The CHEK2 1100delC mutation thus provided conclu-
sive genetic evidence for the existence of an HBCC sub-
type of familial breast cancer.
We identified 55 families with HBCC in a series of 435
families with non-BRCA1/BRCA2 breast cancer from
the Rotterdam family cancer clinic, representing 13% of
the total (table 1). Examples of pedigrees with HBCC are
shown in figure 1. Of the 55 families with HBCC, 17
(31%) had been included by the first HBCC criterion, 7
(13%) by the second criterion, and 21 (38%) by the
third criterion (see list above). Ten (18%) families met
multiple HBCC criteria, and five of these carried the
CHEK2 1100delC mutation. Forty-five families with
HBCC also included cancers from anatomical sites other
than the mammary glands or colorectum, with an av-
erage of almost three cases per family (altogether 129
other cancers, excluding basal cell carcinomas). None of
these 45 families with HBCC had a cancer pattern
reminiscent of the Li-Fraumeni syndrome (LFS [MIM
151623]) (Bell et al. 1999).
We assessed cosegregation of the CHEK2 1100delC
genotype with the disease phenotype for nine informa-
tive families with breast cancer from the two Rotterdam
family cohorts. Cosegregation was incomplete for five
of these nine families. Among first- and second-degree
relatives of the index patients, only 7 of 13 (54%) typed
patients with breast cancer carried the CHEK2 1100delC
mutation. The age at breast cancer diagnosis was similar
for the mutation carriers and the noncarriers (52.7 vs.
56.8 years; ), and double tumors were not ob-Pp .63
served among these 13 additionally typed patients with
breast cancer. When colorectal cancer was considered to
be part of the phenotype, 9 of 16 (56%) patients carried
the mutant allele. For comparison, we observed cose-
gregation of the family-specific mutation with the disease
phenotype for 86% of additionally typed patients with
breast and ovarian cancer from families with BRCA1
and BRCA2 mutations (Meijers-Heijboer et al., in press),
indicating that the incomplete cosegregation of the
CHEK2 1100delC mutation could not be explained just
by the presence of sporadic breast or colorectal cancer
cases in the families. Cosegregation was also incomplete
for all three informative families with CHEK2 1100delC
colorectal cancer, where none of five additionally typed
patients with colorectal cancer carried the mutant allele.
Three of the six families with CHEK2 1100delC colo-
rectal cancer also carried a pathogenic mutation of a
mismatch-repair gene. In the family with MLH1 HNPCC,
three patients with colorectal cancer were carriers of the
MLH1 mutation, two were obligate carriers, and none
were known to be a noncarrier of the MLH1 mutation.
Two patients with MLH1 colorectal cancer were avail-
able for typing. One of these also carried the CHEK2
1100delC mutation and was diagnosed with colorectal
cancer at age 34 years and with endometrial cancer at
age 55 years. The other patient was a noncarrier of the
CHEK2 1100delC mutation and was diagnosed with
colorectal cancer at age 52 years. In the family with
MSH2 HNPCC, one patient with colorectal cancer was
diagnosed at age 30 years and was carrier of both the
MSH2 mutation and the CHEK2 1100delC mutation.
Another patient with colorectal cancer from this family
was diagnosed at age 37 years and was a noncarrier of
the MSH2 mutation but was not available for CHEK2
1100delC typing. In the family with MSH6 HNPCC,
two patients with colorectal cancer were carriers of the
MSH6 mutation, one was an obligate carrier, and none
were known to be noncarriers of the MSH6 mutation.
Of the two MSH6 mutation carriers, one was diagnosed
with colorectal cancer at age 65 years and also carried
the CHEK2 1100delC mutation. The other MSH6 mu-
tation carrier was diagnosed with colorectal cancer at
age 45 years and with endometrial cancer at age 54
years, but did not carry the CHEK2 1100delC mutation.
The CHEK2 1100delC mutation is an unusual cancer-
susceptibility allele, in that not all patients with breast
or colorectal cancer from the families with the CHEK2
1100delC mutation carry the mutant allele, even though
the mutant allele was significantly associated with their
familial clustering of breast and colorectal cancer (Mei-
jers-Heijboer et al. 2002; Vahteristo et al. 2002; the pre-
sent study). We hypothesize that the CHEK2 1100delC
mutation acts in synergy with another, as-yet-unknown
cancer-susceptibility gene or genes. Thus, the estimated
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twofold increase in breast cancer risk for CHEK2
1100delC mutation carriers (Meijers-Heijboer et al. 2002)
represents a surplus to the cancer risk among the families
with CHEK2 1100delC that is due to the unknown sus-
ceptibility gene. Considering the generally high-penetrant
cancer-predisposition pattern among the families with
the CHEK2 1100delC mutation (fig. 1), the unknown
susceptibility gene would appear to be at least moder-
ately penetrant or low penetrant in a more complex pol-
ygenic model. If this is true, one may comprehend that
the CHEK2 1100delC mutation tends to associate with
the more severely affected families with breast cancer
(Meijers-Heijboer et al. 2002; the present study), even
though the increased breast cancer risk conferred by the
CHEK2 1100delC mutation is estimated to be only a
modest twofold. Also, the CHEK2 1100delC mutation
would not completely cosegregate but merely associate
with the cancer phenotype, since it confers only a surplus
of cancer risk. Two recent reports suggested a synergistic
role of CHEK2 at the intra-S phase checkpoint of the
cell division cycle. Using a variety of human cells defec-
tive in DNA damage–response proteins, it was shown
that ATM-dependent radio-sensitive DNA synthesis
(RDS) diverges via the CHEK2-CDC25A-CDK2 pathway
and the MRE11-RAD50-NBS1 pathway. Whereas each
of these pathways induced a partial replication block
upon ionizing radiation, complete inhibition of RDS was
achieved only by concerted action of both pathways
(Falck et al. 2002) (ATM [MIM 208900], CDC25A
[MIM 116947], CDK2 [MIM 116953], MRE11 [MIM
600814], RAD50 [MIM 604040], and NBS1 [MIM
602667]). In S. cerevisiae, mutation of the CHEK2 ho-
mologue RAD53 caused a modest increase in the rate of
spontaneous gross chromosomal rearrangements (GCR),
whereas double mutants of RAD53 and TEL1 (hATM)
had a highly synergistic effect on the GCR rate (Myung
et al. 2001). Perhaps the putative HBCC-susceptibility
gene should be looked for among candidates that are
known to function in suppression of genome instability
at the intra-S phase checkpoint of the cell cycle.
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